The International Myositis Assessment and Clinical Studies Group (IMACS) have published evidence and consensus based cancer screening guidelines for patients with idiopathic inflammatory myopathies, including dermatomyositis.
A retrospecitive analysis of 62 patients with systemic vasculitis complicated by Pneumocystis jirovecii pneumonia (PJP) showed those with microscopic polyangiitis (MPA) had a higher mortality risk, possibly due to a higher prevalence of interstitial lung disease (ILD) in MPA.
Dr. John Cush RheumNow
2 years ago
Limited Efficacy of Muscle Relaxants for Chronic Pain
A systematic review of long-term muscle relaxant use for chronic pain suggests they may be effective in treating trigeminal neuralgia, cramps, and neck pain, but not fibromyalgia, low back pain, and other pain syndromes.… https://t.co/sReBxhSpWH https://t.co/tQGWKPwokn
Since 2022, EULAR and the Paediatric Rheumatology European Society (PReS) have been working to establish clinical practice guidelines for the diagnostics and management of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD).
Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.
Dr. John Cush RheumNow
2 years ago
I Can't Treat Ugly (9.20.2024)
Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.
https://t.co/mSI16Ug4iR https://t.co/arCx6yo5p6
Dr. John Cush RheumNow
2 years ago
TUDOR study looked at the incidence of PsA by serially following primary care psoriasis pts. At 1 year, 14/511 developed PsA (incidence 2.74 per 100 p-yrs) and at 2 years 7/444 developed PsA (1.58/100 p-yrs). Combined incidence @2 yrs - 2.2 per 100 p-yrs https://t.co/pbHBWt0pXn https://t.co/tHMhQs1cqN
Dr. John Cush RheumNow
2 years ago
ACR 2024 Abstracts are available.
Let the fun begin.....
https://t.co/uNLZBqjEX0
Search by term, title or abstract # here: https://t.co/Du1eN4gA9D
or
Search by sessions and topics here >> https://t.co/R7NH1jeHPj https://t.co/OCoTPr03nG
An exhaustive, full read guideline from the British Association of Dermatologists (BAD) and the British Society for Rheumatology (BSR) on the management and treatment of Behçet’s disease (BD) in 2024 has been published in Rheumatology.
Dr. John Cush RheumNow
2 years ago
Korean Epidemiologic study shows the prevalence of Psoriatic arthritis has increased fbetween 2008 and 2020. Prevalence was 6/1000 in 2008 & 19/1000 in 2020. PsA incidence also incr from 3.35 to 5.01/1000 in the same era https://t.co/d20zETK2q2 https://t.co/WAuqoHFDfu
Dr. John Cush RheumNow
2 years ago
Danish cross-sectional survey 12 713 Inflam arthritis (RA, PsA, SpA) pts & found lonliness in one-third (RA 32%; 36% in PsA & SpA) and highest in SpA w/ depression (66%). Loneliness was correlated w/ disease activity. https://t.co/Q3IswbIwe6 https://t.co/GNohOkkmEw
Dr. John Cush RheumNow
2 years ago
Full read overview of ILD & its Clinical Course inRheumatoid Arthritis. Metanalysis of 22 reports shows 6-19% of RA have ILD on HRCT. Article discusses early onset, progression and the monitoring and management of RA-ILD https://t.co/mqexPcruni https://t.co/One7XYn4wX
The INVIGORATE-2 trial reports that intravenous secukinumab is both effective and safe in patients with active psoriatic arthritis, demonstrating improvements on par with subcutaneous secukinumab.
Dr. John Cush RheumNow
2 years ago
Analysis of 5 Nordic registries & 29,478 RA & 10,919 PsA pts initiating 1st bDMARD,s
(& 362,087 pop controls). Incident ILD was higher in RA (HR 9.7) & PsA (4.4). but MTX co-use (vs non-use) did not incr ILD in RA (HR 0.9; 0.7, 1.2) or PsA (HR 1.0) https://t.co/xY8COh85Bw https://t.co/weJGirfhDX
